UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

European journal of immunology, 2003-10, Vol.33 (10), p.2706-2716

2003

Volltextzugriff (PDF)

Tissue expression of PD-L1 mediates peripheral T cell tolerance

The Journal of experimental medicine, 2006-04, Vol.203 (4), p.883-895

2006

Volltextzugriff (PDF)

PD-L1-Deficient Mice Show That PD-L1 on T Cells, Antigen-Presenting Cells, and Host Tissues Negatively Regulates T Cells

Proceedings of the National Academy of Sciences - PNAS, 2004-07, Vol.101 (29), p.10691-10696

2004

Volltextzugriff (PDF)

Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model

Cancer Immunology, Immunotherapy, 2011-04, Vol.60 (4), p.547-558

2011

Volltextzugriff (PDF)

Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes

Journal of Immunology, 2005-12, Vol.175 (11), p.7372-7379

2005

Volltextzugriff (PDF)

PD‐L1 and PD‐L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis

European Journal of Immunology, 2006-01, Vol.36 (1), p.58-64

2006

Volltextzugriff (PDF)

Auto-antibody production and glomerulonephritis in congenic Slamf1-/- and Slamf2-/- [B6.129] but not in Slamf1-/- and Slamf2-/- [BALB/c.129] mice

International immunology, 2011-02, Vol.23 (2), p.149-158

2011

Volltextzugriff (PDF)

Negative co-receptors on lymphocytes

Current Opinion in Immunology, 2002-06, Vol.14 (3), p.391-396

2002

Volltextzugriff (PDF)

PD-L1/PD-1 Signal Deficiency Promotes Allogeneic Immune Responses and Accelerates Heart Allograft Rejection

Transplantation, 2008-09, Vol.86 (6), p.836-844

2008

Volltextzugriff (PDF)

712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A754-A754

2020

Volltextzugriff (PDF)

Cutting Edge: Identification of the 2B4 Molecule as a Counter-Receptor for CD48

The Journal of immunology (1950), 1998-12, Vol.161 (11), p.5809-5812

1998

Volltextzugriff (PDF)

Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions

Blood, 2006-04, Vol.107 (8), p.3181-3188

2006

Volltextzugriff (PDF)

The SLAM family member CD48 ( Slamf2 ) protects lupus-prone mice from autoimmune nephritis

Journal of autoimmunity, 2011-08, Vol.37 (1), p.48-57

2011

Volltextzugriff (PDF)

Suppression of FVIII Inhibitor Formation in Hemophilic Mice by Delivery of Transgene Modified Apoptotic Fibroblasts

Molecular therapy, 2010-01, Vol.18 (1), p.214-222

2010

Volltextzugriff (PDF)

Distinct changes in adult lymphopoiesis in Rag2−/− mice fully reconstituted by α4-deficient adult bone marrow cells

Experimental hematology, 2008-08, Vol.36 (8), p.1004-1013

2008

Volltextzugriff (PDF)

Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model

Blood, 2017-08, Vol.130 (8), p.1052-1061

2017

Volltextzugriff (PDF)

CD48-Deficient Mice Have a Pronounced Defect in CD4+T Cell Activation

Proceedings of the National Academy of Sciences - PNAS, 1999-02, Vol.96 (3), p.1019-1023

1999

Volltextzugriff (PDF)

Immunomodulatory Effects of Transfusion

Blood, 2015-12, Vol.126 (23), p.1144-1144

2015

Volltextzugriff (PDF)

Transfusion‐related immunomodulation: gamma irradiation alters the effects of leukoreduction on alloimmunization

Transfusion (Philadelphia, Pa.), 2019-11, Vol.59 (11), p.3396-3404

2019

Volltextzugriff (PDF)

Abstract 4537: SBT6050, a HER2-directed TLR8 ImmunoTAC™therapeutic, is a potent human myeloid cell agonist that provides opportunity for single agent clinical activity

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4537-4537

2020

Volltextzugriff (PDF)

SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3110-3110

2020

Volltextzugriff (PDF)

Abstract 2363: Combinational therapy with specific immunization plus checkpoint inhibition results in enhanced tumor regression and survival benefit

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2363-2363

2016

Volltextzugriff (PDF)

Abstract PD4-09: Preclinical studies support the development of SBT6050, an anti-HER2 antibody conjugated to a potent TLR8 agonist, for treatment of moderate and high HER2-expressing tumors that lack pre-existing T cell infiltrate

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD4-09-PD4-09

2020

Volltextzugriff (PDF)

Abstract 1858: SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC™ product candidate, is designed for tumor-localized activation of myeloid cells

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1858-1858

2021

Volltextzugriff (PDF)

Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer

Cancer Immunology, Immunotherapy, 2015-08, Vol.64 (8), p.977-987

2015

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(55)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Animals
(23)
Life Sciences & Biomedicine
(23)
Mice
(20)
Immunology
(18)
Mice, Knockout
(12)
B7-H1 Antigen
(10)
T-Lymphocytes - Immunology
(8)
Humans
(7)
Mice, Inbred C57bl
(7)
Antigens
(6)
Antigens, Cd - Genetics
(6)
Antigens, Cd - Immunology
(6)
Immunotherapy
(6)
Mice, Inbred Balb C
(6)
Peptides - Immunology
(6)
Programmed Cell Death 1 Ligand 2 Protein
(6)
Biological And Medical Sciences
(5)
Cd4-Positive T-Lymphocytes - Immunology
(5)
Cd48 Antigen
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

Tissue expression of PD-L1 mediates peripheral T cell tolerance

PD-L1-Deficient Mice Show That PD-L1 on T Cells, Antigen-Presenting Cells, and Host Tissues Negatively Regulates T Cells

Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model

Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes

PD‐L1 and PD‐L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis

Auto-antibody production and glomerulonephritis in congenic Slamf1-/- and Slamf2-/- [B6.129] but not in Slamf1-/- and Slamf2-/- [BALB/c.129] mice

Negative co-receptors on lymphocytes

PD-L1/PD-1 Signal Deficiency Promotes Allogeneic Immune Responses and Accelerates Heart Allograft Rejection

712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors

Cutting Edge: Identification of the 2B4 Molecule as a Counter-Receptor for CD48

Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions

The SLAM family member CD48 ( Slamf2 ) protects lupus-prone mice from autoimmune nephritis

Suppression of FVIII Inhibitor Formation in Hemophilic Mice by Delivery of Transgene Modified Apoptotic Fibroblasts

Distinct changes in adult lymphopoiesis in Rag2−/− mice fully reconstituted by α4-deficient adult bone marrow cells

Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model

CD48-Deficient Mice Have a Pronounced Defect in CD4+T Cell Activation

Immunomodulatory Effects of Transfusion

Transfusion‐related immunomodulation: gamma irradiation alters the effects of leukoreduction on alloimmunization

Abstract 4537: SBT6050, a HER2-directed TLR8 ImmunoTAC™therapeutic, is a potent human myeloid cell agonist that provides opportunity for single agent clinical activity

SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist

Abstract 2363: Combinational therapy with specific immunization plus checkpoint inhibition results in enhanced tumor regression and survival benefit

Abstract PD4-09: Preclinical studies support the development of SBT6050, an anti-HER2 antibody conjugated to a potent TLR8 agonist, for treatment of moderate and high HER2-expressing tumors that lack pre-existing T cell infiltrate

Abstract 1858: SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC™ product candidate, is designed for tumor-localized activation of myeloid cells

Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer

Suchergebnisse filtern